From Dallas Express · Dallas Express · · 1m 30s
A new SMA drug goes after the muscle itself
Isembyld is the first SMA therapy cleared to treat muscle loss directly, and it works on top of the drugs patients already take.
In brief
Isembyld is the first SMA therapy cleared to treat muscle loss directly, and it works on top of the drugs patients already take. Existing SMA drugs protect motor neurons but don't stop muscle decline. Isembyld is the first approved add-on aimed at the muscle itself, with a real fracture risk attached. Originally…
FDA clears Isembyld
Scholar Rock said on September 11 that the FDA approved Isembyld, also called apitegromab-mstn, for spinal muscular atrophy. Shipments start within days.
Who can get it
Approval covers patients aged 2 and up who are already on an SMN2-targeted treatment. It is an add-on, not a replacement.
Why muscle is the gap
SMA comes from a faulty SMN1 gene, starving motor neurons of a protein they need. Current drugs restore that protein, but people with advanced disease still lose movement.
It blocks myostatin
Myostatin is a protein that limits muscle growth. Isembyld stops it from activating, making this the first approved SMA therapy aimed at muscle loss itself.
“This is what progress looks like”
The trial numbers
In a 52-week trial of 188 people aged 2 to 21, 34.2% of treated children aged 2 to 12 hit clinically meaningful motor improvement versus 13.5% on placebo.
The risks are real
Fractures, including serious ones, went up. Respiratory infections, vomiting, cough and headache were common, and the FDA flagged possible fetal harm and reproductive effects.
What matters most
Existing SMA drugs protect motor neurons but don't stop muscle decline. Isembyld is the first approved add-on aimed at the muscle itself, with a real fracture risk attached.
